| Name | Title | Contact Details |
|---|
YM BioSciences Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
NeuroVista Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At ImmunoFlex™ we share an interest in understanding the human immune system and how different compounds have the potential to strengthen, support, and enhance our body`s natural surveillance and response system.
BioHitech America is the industry leader in the development of a simple, cost-effective food waste disposal technology designed to solve today’s landfill diversion and sustainability objectives. The Eco-Safe Digester handles food waste at the point of generation, no residual food waste to store or transport. The Eco-Safe Digester can convert up to 2,400 pounds of food waster per day into a nutrient-neutral grey water that can safely be disposed of via municipal sewer systems. The Eco-Safe Digester saves money by avoiding disposal costs and significantly reduces greenhouse gas emissions by providing a sustainable means of transportation for the waste by-product with doesn’t require on-road transportation. The Eco-Safe Digester’s cloud-based management solution is designed to measure and collect food waste data. It correlates information to report cost savings and environmental reductions as well as communicate opportunities to prevent waste altogether. This modifiable data can also be used to assess the performance of your staff and predict trends for smarter budgeting and purchasing purposes. In addition to diverting food waste from landfills and converting food waste into a resource, the machine is now poised for significant growth in this emerging data-driven zero waste initiative climate because it identifies waste in order to prevent the creation of it all together. Already implemented in many applications across the globe, the Eco-Safe Digester is ideal for use in any food service, hospitality, healthcare, government, conference center, education center, or stadium that generates a high volume of waste.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.